THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS
Objective. To evaluated effect of adalimumab treatment on activity of arthritis, enthesitis, psoriasis and functional status in PsA patients (pts). Subjects and methods. 18 pts with active PsA (12 female, 6 male), median age 43,1±10,2 years (yrs) (range 24-56), median duration of psoriasis 16,7±9,6...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2010-06-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/586 |
| _version_ | 1797862842083311616 |
|---|---|
| author | Elena Yurievna Loginova T V Korotaeva N V Klimova E N Aleksandrova L N Denisov Sh F Erdes |
| author_facet | Elena Yurievna Loginova T V Korotaeva N V Klimova E N Aleksandrova L N Denisov Sh F Erdes |
| author_sort | Elena Yurievna Loginova |
| collection | DOAJ |
| description | Objective. To evaluated effect of adalimumab treatment on activity of arthritis, enthesitis, psoriasis and functional status in PsA patients (pts). Subjects and methods. 18 pts with active PsA (12 female, 6 male), median age 43,1±10,2 years (yrs) (range 24-56), median duration of psoriasis 16,7±9,6 yrs (range 4-33), median duration of PsA 9,2±6,7 yrs (range 1,5-23) received Adalimumab 40 mg subcutaneously every other week (wk) for 12 wks in open-label study. Evaluations of treatment effects were conducted by the PSARC, ACR 20, 50 and 70, LEI, PASI, BSA, HAQ and CRP at wks 4 and 12. Results. The sings of activity of PsA at baseline were: DAS=4,8 (4,0; 5,45), LEI=4,25 (0,25; 8,05), PASI=10,5 (7,2; 12,1), BSA=1,75 (1; 2), HAQ=1,125 (0,875; 1,5), СRР=27,9 (11,4; 34,6). After 4 wks all parameters significantly improved: DAS=2,85 (2,1; 3,1), LEI=1,86 (0; 3,97), PASI=6,4 (2,8; 8), BSA=0,75 (0,15; 1), HAQ=0,375 (0,125; 0,625), СRP=1,7 (1,4; 3,2) and were maintained after 12 wks: DAS=1,6 (1,3; 2,03), LEI=0,38 (0; 0,89), PASI=1,1 (0,4; 2,2), BSA=0 (0; 0,9), HAQ=0,312 (0; 0,625), СRР=1,75 (0,7; 3,6); p |
| first_indexed | 2024-04-09T22:27:14Z |
| format | Article |
| id | doaj.art-4ffa4540a94745d88f842796985e806e |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2024-04-09T22:27:14Z |
| publishDate | 2010-06-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-4ffa4540a94745d88f842796985e806e2023-03-22T13:45:45ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922010-06-01483838710.14412/1995-4484-2010-448526THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITISElena Yurievna LoginovaT V KorotaevaN V KlimovaE N AleksandrovaL N DenisovSh F ErdesObjective. To evaluated effect of adalimumab treatment on activity of arthritis, enthesitis, psoriasis and functional status in PsA patients (pts). Subjects and methods. 18 pts with active PsA (12 female, 6 male), median age 43,1±10,2 years (yrs) (range 24-56), median duration of psoriasis 16,7±9,6 yrs (range 4-33), median duration of PsA 9,2±6,7 yrs (range 1,5-23) received Adalimumab 40 mg subcutaneously every other week (wk) for 12 wks in open-label study. Evaluations of treatment effects were conducted by the PSARC, ACR 20, 50 and 70, LEI, PASI, BSA, HAQ and CRP at wks 4 and 12. Results. The sings of activity of PsA at baseline were: DAS=4,8 (4,0; 5,45), LEI=4,25 (0,25; 8,05), PASI=10,5 (7,2; 12,1), BSA=1,75 (1; 2), HAQ=1,125 (0,875; 1,5), СRР=27,9 (11,4; 34,6). After 4 wks all parameters significantly improved: DAS=2,85 (2,1; 3,1), LEI=1,86 (0; 3,97), PASI=6,4 (2,8; 8), BSA=0,75 (0,15; 1), HAQ=0,375 (0,125; 0,625), СRP=1,7 (1,4; 3,2) and were maintained after 12 wks: DAS=1,6 (1,3; 2,03), LEI=0,38 (0; 0,89), PASI=1,1 (0,4; 2,2), BSA=0 (0; 0,9), HAQ=0,312 (0; 0,625), СRР=1,75 (0,7; 3,6); phttps://rsp.mediar-press.net/rsp/article/view/586psoriatic arthritisadalimumabenthesitispsoriasis |
| spellingShingle | Elena Yurievna Loginova T V Korotaeva N V Klimova E N Aleksandrova L N Denisov Sh F Erdes THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS Научно-практическая ревматология psoriatic arthritis adalimumab enthesitis psoriasis |
| title | THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS |
| title_full | THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS |
| title_fullStr | THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS |
| title_full_unstemmed | THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS |
| title_short | THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS |
| title_sort | first russian experience of adalimumab treatment in psoriatic arthritis |
| topic | psoriatic arthritis adalimumab enthesitis psoriasis |
| url | https://rsp.mediar-press.net/rsp/article/view/586 |
| work_keys_str_mv | AT elenayurievnaloginova thefirstrussianexperienceofadalimumabtreatmentinpsoriaticarthritis AT tvkorotaeva thefirstrussianexperienceofadalimumabtreatmentinpsoriaticarthritis AT nvklimova thefirstrussianexperienceofadalimumabtreatmentinpsoriaticarthritis AT enaleksandrova thefirstrussianexperienceofadalimumabtreatmentinpsoriaticarthritis AT lndenisov thefirstrussianexperienceofadalimumabtreatmentinpsoriaticarthritis AT shferdes thefirstrussianexperienceofadalimumabtreatmentinpsoriaticarthritis AT elenayurievnaloginova firstrussianexperienceofadalimumabtreatmentinpsoriaticarthritis AT tvkorotaeva firstrussianexperienceofadalimumabtreatmentinpsoriaticarthritis AT nvklimova firstrussianexperienceofadalimumabtreatmentinpsoriaticarthritis AT enaleksandrova firstrussianexperienceofadalimumabtreatmentinpsoriaticarthritis AT lndenisov firstrussianexperienceofadalimumabtreatmentinpsoriaticarthritis AT shferdes firstrussianexperienceofadalimumabtreatmentinpsoriaticarthritis |